Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA2315234
Max Phase: Preclinical
Molecular Formula: C45H52F3N9O8S
Molecular Weight: 822.00
Molecule Type: Small molecule
Associated Items:
ID: ALA2315234
Max Phase: Preclinical
Molecular Formula: C45H52F3N9O8S
Molecular Weight: 822.00
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: C[C@@H]1CN2CC(=O)Nc3ccc(cc3)C[C@@H](C(=O)NCc3ccc(C(=N)N)cc3)NC(=O)[C@H](NS(=O)(=O)Cc3ccccc3)Cc3ccc(cc3)NC(=O)CN1C[C@@H]2C.O=C(O)C(F)(F)F
Standard InChI: InChI=1S/C43H51N9O6S.C2HF3O2/c1-28-24-52-26-40(54)48-36-18-12-31(13-19-36)21-38(50-59(57,58)27-33-6-4-3-5-7-33)43(56)49-37(42(55)46-22-32-8-14-34(15-9-32)41(44)45)20-30-10-16-35(17-11-30)47-39(53)25-51(28)23-29(52)2;3-2(4,5)1(6)7/h3-19,28-29,37-38,50H,20-27H2,1-2H3,(H3,44,45)(H,46,55)(H,47,53)(H,48,54)(H,49,56);(H,6,7)/t28-,29+,37-,38+;/m0./s1
Standard InChI Key: ILXNFZFJPGWGAV-NSDLUCIFSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 822.00 | Molecular Weight (Monoisotopic): 821.3683 | AlogP: 2.33 | #Rotatable Bonds: 8 |
Polar Surface Area: 218.92 | Molecular Species: BASE | HBA: 9 | HBD: 7 |
#RO5 Violations: 2 | HBA (Lipinski): 15 | HBD (Lipinski): 8 | #RO5 Violations (Lipinski): 3 |
CX Acidic pKa: 9.10 | CX Basic pKa: 11.34 | CX LogP: 1.88 | CX LogD: 0.34 |
Aromatic Rings: 4 | Heavy Atoms: 59 | QED Weighted: 0.10 | Np Likeness Score: -0.23 |
1. Saupe SM, Leubner S, Betz M, Klebe G, Steinmetzer T.. (2013) Development of new cyclic plasmin inhibitors with excellent potency and selectivity., 56 (3): [PMID:23294255] [10.1021/jm3012917] |
Source(1):